NEW YORK, July 21 (GenomeWeb News) - Molecular Devices yesterday said slumping sales of its imaging products helped turn a profit into a loss during the second quarter despite overall revenue growth.

Revenues for the quarter ended June 30 grew 6.5 percent to $47.4 million from $44.5 million the same period last year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.